目的 探讨吉非替尼治疗晚期非小细胞肺癌患者的临床疗效及安全性,观察治疗前后肿瘤标志物血清胚抗原变化。方法2008年12月至2013年12月在我院治疗的晚期非小细胞肺癌患者36例，给予吉非替尼口服250mg/d，直至出现疾病进展或副作用不能耐受而停止治疗。结果 36例均可评定疗效，临床受益率为77.8%。11例获PR，17例获SD， 11例获PD，总有效率30.6%，疾病控制率为77.8%。中位随访时间 9个月(1～33月)。中位无进展生存期4个月，中位生存时间9个月。1年生存率38.9 %，2年生存率22.2%。最长1 例存活30.3个月。药物不良反应主要为：皮疹，腹泻，肝功能异常等。患者癌胚抗原治疗后较治疗前明显下降。结论吉非替尼治疗晚期非小细胞肺癌疗效较好，特别女性和腺癌更加明显，毒副反应相对较轻，血清癌胚抗原水平可以作为检测吉非替尼对晚期非小细胞肺癌疗效的指标。值得临床进一步推广使用。

Objective To study the value of serum carcinoembryonic antigen in monitoring the clinical effect of Gefitinib on treatment of advanced stage non-small cell lung cancer. Methods 36 cases of patients with advanced non small cell lung cancer were given Gefitinib orally 250mg/d, until disease progression or intolerance of side effects. The serum CEA levels in patients before and after treatment were determined. Results The clinical benefit response rate of Gefitinib treatment in patients with advanced non small cell lung cancer reached 77.8%. Among all the cases, there were 11 cases of PR, 17 cases of SD and 11 cases of PD. The total effective rate was 30.6% and disease control rate was 77.8%. Median survival time without tumor was 4 months, and median overall survival time was 9 months. The one year and two years survival rate was 38.9% and 22.2% respectively. One case even survived 30.3 months. The serum CEA levels in patients after treatment were significantly lower than that of before treatment. Conclusion The treatment effect of Gefitinib in advanced non small cell lung cancer effect is better, especially in women and adenocarcinoma patients. The serum CEA level could be used an index to monitor the treatment effect of Gefitinib in advanced non small cell lung cancer.